Epitope-dependent differential immunoreactivities of anti-MUC1 monoclonal antibodies in human carcinomas

被引:0
|
作者
Baldus, SE
Goergen, D
Hanisch, FG
Dienes, HP
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Univ Cologne, Fac Med, Ctr Biochem, D-50924 Cologne, Germany
关键词
monoclonal antibodies; MUC1; epitope; cancer therapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
According to studies on a variety of malignant tumors from different organs MUC1 mucin antigen presents as a valuable marker of cancer progression and prognosis. During recent years, a great number of monoclonal antibodies (mabs) directed to MUC1 was generated. Their epitopes can be classified according to their position within the tandem repeat domain of the mucin and with respect to effects exerted by site-specific glycosylation. In this study, eight mabs from different clusters were selected to correlate their epitope specificity with their binding pattern in human cancer specimens. By applying an immunohistochemical ABC-peroxidase method, ten carcinomas derived from breast, pancreas, stomach and colon were characterized. A positive reaction of all mabs could be observed in the majority of the carcinomas, however, the extent of the stained tumor area varied significantly. In general, mabs M38, VA1 and BC3 exhibited the strongest staining reaction. Mab BW835 showed a similar binding intensity, especially in pancreatic and gastric carcinomas. It is tempting to speculate that the different binding patterns may reflect differences in epitope specificity. In conclusion, future immunohistochemical, immunoserological and therapeutic studies involving MUC1 antigen should prefer well-characterized and highly reactive mabs detecting defined peptide epitopes.
引用
收藏
页码:507 / 512
页数:6
相关论文
共 50 条
  • [1] Epitope mapping of anti-MUC1 mucin protein core monoclonal antibodies
    Petrakou, E
    Murray, A
    Price, MR
    TUMOR BIOLOGY, 1998, 19 : 21 - 29
  • [2] Evaluation of Pepscan analyses for epitope mapping of anti-MUC1 monoclonal antibodies - a comparative study and review of five antibodies
    Petrakou, E
    Murray, A
    Rosamund, C
    Graves, L
    Price, MR
    ANTICANCER RESEARCH, 1998, 18 (6A) : 4419 - 4421
  • [3] Talc and anti-MUC1 antibodies
    Muscat, J
    Huncharek, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2679 - 2679
  • [4] Design of ligands for the purification of anti-MUC1 antibodies by peptide epitope affinity chromatography
    Murray, A
    Spencer, DIR
    Missailidis, S
    Denton, G
    Price, MR
    JOURNAL OF PEPTIDE RESEARCH, 1998, 52 (05): : 375 - 383
  • [5] Talc and anti-MUC1 antibodies - Response
    Cramer, DW
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2680 - 2680
  • [6] Combination of anti-MUC1 and anti-cripto-1 monoclonal antibodies in breast cancer therapy
    Yang, E
    Li, J
    Hu, XF
    Sandrin, M
    Xing, PX
    TISSUE ANTIGENS, 2005, 66 (05): : 597 - 597
  • [7] Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas
    Denton, G
    Sekowski, M
    Spencer, DIR
    Hughes, ODM
    Murray, A
    Denley, H
    Tendler, SJB
    Price, MR
    BRITISH JOURNAL OF CANCER, 1997, 76 (05) : 614 - 621
  • [8] Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas
    G Denton
    M Sekowski
    DIR Spencer
    ODM Hughes
    A Murray
    H Denley
    SJB Tendler
    MR Price
    British Journal of Cancer, 1997, 76 : 614 - 621
  • [9] 2ND-GENERATION ANTI-MUC1 PEPTIDE MONOCLONAL-ANTIBODIES
    XING, PX
    PRENZOSKA, J
    QUELCH, K
    MCKENZIE, IFC
    CANCER RESEARCH, 1992, 52 (08) : 2310 - 2317
  • [10] Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity
    Mazor, Y
    Keydar, I
    Benhar, I
    MOLECULAR IMMUNOLOGY, 2005, 42 (01) : 55 - 69